Molecular size (~2.7KDa) and amphipathic character of ReAlta’s peptides enable efficient tissue penetration
Simultaneous and independent inhibition of complement and neutrophil effectors at the most destructive stages of the inflammatory cascade
Small molecular size enables ReAlta’s peptides to cross an intact blood-brain barrier
No off-target effects as ReAlta’s peptides exert their activity extracellularly
Proprietary peptides do not generate anti-drug antibodies
Multiple routes of administration
